Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 3/20 | 0.35 |
| ▸ | NOS2 | P35228 | 3/20 | 0.35 |
| ▸ | NOS3 | P29474 | 2/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | PRKCA | P17252 | 4/20 | 0.31 |
| ▸ | PRKCE | Q02156 | 4/20 | 0.31 |
| ▸ | FUCA1 | P04066 | 8/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4813300 | 1.00 | ALOX5 (0.48) | ALOX5ALDH1A1NOS1NOS2NOS3 | |
| SCHEMBL176362 | 0.84 | — | — | |
| SCHEMBL726033 | 0.83 | ALOX5 (0.61) | ALOX5ALDH1A1NOS1NOS2NOS3 | |
| SCHEMBL1437889 | 0.81 | ALOX5 (0.50) | ALOX5ALDH1A1NOS1NOS2NOS3 | |
| SCHEMBL1573174 | 0.81 | ALOX5 (0.50) | ALOX5ALDH1A1NOS1NOS2NOS3 | |
| SCHEMBL4557504 | 0.81 | ALOX5 (0.50) | ALOX5ALDH1A1NOS1NOS2NOS3 | |
| SCHEMBL29971764 | 0.81 | ALOX5 (0.65) | ALOX5ALDH1A1EPHX1 | |
| SCHEMBL18657390 | 0.81 | ALOX5 (0.65) | ALOX5ALDH1A1EPHX1 | |
| SCHEMBL18685663 | 0.81 | ALOX5 (0.65) | ALOX5ALDH1A1EPHX1 | |
| SCHEMBL15259506 | 0.81 | ALOX5 (0.52) | ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7468389-B2 | Carboxylic acid compound having cyclopropane ring | TOX K.K. (JP) | 2008-12-23 | — | — | US | disclosed |
| EP-1343746-B1 | USE OF CARBOXYLIC ACID COMPOUND HAVING CYCLOPROPANE RING AS MEDICAMENT | TOX KK (JP) | 2006-06-14 | — | — | EP | disclosed |
| US-20050075393-A1 | Carboxylic acid compound cyclopropane ring | NISHIZAKI BIOINFORMATION RESEARCH INSTITUTE (JP) | 2005-04-07 | — | — | US | disclosed |
| EP-1343746-A1 | CARBOXYLIC ACID COMPOUND HAVING CYCLOPROPANE RING | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-09-17 | — | — | EP | disclosed |
| WO-2002050013-A1 | CARBOXYLIC ACID COMPOUND HAVING CYCLOPROPANE RING | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075393-A1 | Carboxylic acid compound cyclopropane ring | SLC1A2, GRIN1, BDNF | ALOX5 287/4885ALDH1A1 1047/4885NOS1 394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.